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defined within that. The dose enhancement factor (DEF) has 
been calculated to compare the effects of GNPs in laser 
therapy of eye melanoma. In the In Vitro phase of this work 
the uveal Melanoma cells were cultivated in DMEM with 20% 
FBS. In the seventh passage the cells were grown on a 24-
well plate in which the first five wells incubated with 
different concentrations of gold nanoparticles and the sixth 
well saved as control.  
Results and Discussion: The MTT assay was done in order to 
evaluate the toxicity of these nanoparticles, so as to define 
the preferred concentrations of GNPs. After the cytotoxicity 
assay and determination of the concentration range of these 
nanoparticles, the sample has been injected by GNPs, then 
the dosimetry has been done after irradiation of target with 
laser beam. Within a time span of 48 hours, and also a week 
after the injection of the noted substances, viability of cells 
were evaluated with MTT assay. The results show that the 
higher concentration of GNPs show a higher decrease in cell 
viability. Making a comparison between Laser beam, cobalt 
source and low dose rate sources such as Iodine and 
Palladium in the study of the effects of GNPs in cancer 
therapy reports very interesting results and motivated us to 
do a full in vivo study in this regards. Regarding the 
numerous sources that are employed in the radiotherapy of 
the eye Melanoma, the possible effects of these sources, 
whilst accompanied by GNPs, is a matter of heated debate in 
altering the period of treatment and requires more 
comprehensive investigations. A full experimental 
investigation of the effects of GNPs on Choroidal Melanoma 
against different radiation sources could answer this 
question.  
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Carbon ion therapy has been pioneered in USA since 1975[1], 
and in routine clinical use in Japan since 1994[2]. More 
recently, it has also been implemented in Europe (HIT, 
CNAO, MIT and soon MedAustron) and China, and more 
facilities are currently under planning worldwide[3]. The 
rationale behind hadrontherapy with carbon ions has to do 
with their better ballistic properties and higher LET (Linear 
Energy Transfer) when compared to the more widespread 
protons. The drawback being their greater complexity for 
production, planning and delivery[4]. 
Recent improvements in post-accelerated beam technology 
are expanding the range of beams available to include also 
radioactive nuclides, beyond the 12C ion species, currently 
utilized for carbon ion therapy[5]. Furthermore, Monte Carlo 
particle transport codes such as FLUKA[6,7], which has been 
used in this work, are becoming even more refined and 
therefore suitable for use in treatment planning and in-vivo 
verification techniques aiming to improve the treatment dose 
assessment[8].  
In this work, we systematically study the dosimetric 
performance and imaging properties of 11C in a water 
phantom. These add up to the advantages of conventional 12C 
ion therapy a stronger imaging signal, potentiating in-beam 
monitoring, and later dose intake assessment using PET 
instrumentation technologies. In addition to that, a similar 
study has been performed for 15O. 
FLUKA results confirmed the high potential of 11C and 15O in 
imaging, the former presenting no significant absorbed dose 
drawbacks compared to 12C.  
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Purpose: The molecule ODSH has shown great promise in 
preliminary studies suggesting that it improves platelet count 
recovery and impacts survival when the sodium form is given 
as a subcutaneous injection1. A new formulation of the 
molecule will be studied and radiation physics support will be 
provided to assure accuracy of the results. Expansion of the 
program for these studies will include performing dose 
ranging and PK/PD studies in mice for the novel formulation 
as well as some biology studies examining the biology of the 
mechanism of action of the molecule. The dosimetric studies 
will characterize the radiation source in terms of dose rate 
and energy. Maintaining the accuracy and precision of the 
radiation exposure throughout the project is a key factor to 
understanding the biological effects2. Dose uniformity and 
reproducibility will be monitored throughout the project to 
minimize dose uncertainty. 
Materials/Methods: Precision X-ray 3203 was calibrated 
following TG-61 protocol. EBT2 film was exposed at 200, 400, 
600 and 800 cGy to create calibration curve to be used in 
FilmProQA software developed by Ashland technologies. 
Mouse irradiations were taken 320kV, 12.5 mA to a total dose 
of 650 cGy. Gafchromic film was placed under the mice 
during irradiations and later analyzed with FilmProQA4 to 
determine accuracy and uncertainties during the experiment. 
Film exposures were taken at 800 cGy before each 
measurement to adjust the calibrations curve for daily 
variations of the x-ray tube. 
Results: Film analysis determined that dose uniformity in the 
irradiator can vary due to scatter and experimental setup and 
have an effect on the outcome of your experiment.  
Conclusions: For experiments with small animal irradiators a 
quality assurance program should be an integral part of any 
radiation biology study.  
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Purpose: The advent of modern neuroimaging with computed 
tomography (CT) and magnetic resonance (MR) imaging has 
allowed for a better diagnosis and characterization of brain 
abnormalities and diseases. Despite the deep insights offered 
by these imaging methods, their sensitivity and/or spatial 
resolution are insufficient to study the structures of this very 
complex tissue at the cellular level. X-ray phase contrast 
imaging may provide the opportunity to overcome many of 
the limitations affecting current diagnostic methods [1-8].  
Materials/methods: Pre-clinical imaging on the micro- and 
nano-scale with multidimensional resolution (spatial, 
temporal and chemical) is possible when high intensity, 
energy selective and collimated photon beam are used. 
Advanced X-ray phase contrast imaging techniques have been 
developed and used for investigating excised rat and human 
cerebella without the application of any stain or contrast 
agent.  
Results: Images clearly depict the hippocampus and 
cerebellum regions (with white and gray matter) and the 
substantia nigra structure. Normal and tumor tissues are also 
effectively discriminated.  
Conclusions: Proof of principle studies in phase contrast 
micro-CT were performed on irradiated rat brains, 
demonstrating the ability of the method in visualizing not 
only the fine architecture of the organ but also the effects of 
the treatment. Data are validated by comparison with 
histology. This presentation will give an overview of the 
recent results produced in pre-clinical neuroimaging 
research. 
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Purpose: Alanine pellets provided by the National Physical 
Laboratory (UK) have been proposed as a dose verification 
tool in hadron beams. Multiple studies demonstrate a 
relatively weak and reproducible dependence on the mixed 
radiation environment found in Spread out Bragg peaks in ion 
therapy. Quenching effects can be modeled with little effort, 
in conjunction with Monte Carlo particle transport codes [1]. 
Methods: During the in-vivo irradiation with C-12 ions 
presented in the paper [2] several pellets of Alanine were 
positioned at the same SOBP depth where the tumor target 
was located. Alanine pellets were provided and read out by 
NPL in Teddington, UK. The resulting dose-to-water is 
translated to dose-to-alanine, and compared with the 
quenching corrected calculated dose-to-alanine calculated 
with Monte Carlo simulations. 
The Monte Carlo particle transport code FLUKA was used to 
simulate the mixed particle spectrum along the beam. The 
Hansen & Olsen response model [1,3] is provided as a user 
function and linked into the FLUKA runtime.  
Results: Most experimental dose-to-alanine valued agree 
within a few percent to the predicted and quenching 
corrected values. Quenching factors are found to be around 
0.75 at the center of a 3 g/cm2 wide Carbon ion SOBP, 7.3 
g/cm2 deep with a dose average LET of ~60 keV/µm. 
Conclusions: We have successfully demonstrated the use of 
the Alanine dosimeter in an in-vivo dose verification setting. 
Alanine pellets appear to be a robust solid state dosimeter, 
provided information of the mixed radiation field can be 
retrieved by supplemental Monte Carlo calculations. 
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Purpose: Experimental evidence suggests a variable relative 
biological effectiveness (RBE) of clinical proton beams. As 
the spread in data is large a conservative choice of 1.1 is 
used in clinical practice world-wide. Due to an increasing 
interest several radio-biological models have been developed 
trying to represent the complex dependencies that determine 
RBE. We compare predictions obtained from such models for 
clinical-like cranial irradiations. 
Material/methods: Three models proposed in the literature 
[1,2,3] were implemented to an in-house Monte-Carlo-based 
dose forward-calculation engine [4,5]. They were applied to 
